Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- To evaluate target engagement of gaboxadol treatment on high density EEG recordings
研究概览
简要总结
This is a single dose, placebo-controlled study. Male subjects aged 18 to 40 years (inclusive) with a diagnosis of FXS. Eligible subjects may enroll in this study comprised of two in home and two in clinic visits each 14 days apart, for a total of four visits. Subjects will be given single dose gaboxadol (10 mg) or matched placebo at each of these visits to take orally. Thus, all enrolled subjects will receive placebo at home and in clinic and receive gaboxadol at home and in clinic in a blinded fashion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
盲法说明
Quadruple masking (participant, care provider, investigator and outcomes assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subject consents to participate, or if they are not their own legal guardian, offers assent supported by legally authorized representative consent
- •Subject is willing and able to comply with the study procedures as specified in the protocol and to comply with the study drug administration. Caregiver also commits to the study requirements prior to any study-related procedures
- •Subject and caregiver are both able to understand the spoken national language clearly and caregiver can read and write to complete study assessments
- •Males age 18 to 40 years (inclusive)
- •Has FXS with molecular genetic confirmation of the full FMR1 mutation (>200 cysteine-guanine-guanine [CGG] repeats). May have been confirmed historically or at Screening
- •Is in general good health as deemed by the Investigator, determined by physical examination, medical history, and laboratory tests
- •If receiving serotonin-selective reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or serotonin antagonist and reuptake inhibitor (SARI), is on a stable, well-tolerated dose for the previous 3 months with no further changes anticipated
- •Is not sexually active or can confirm at least one form of contraceptive
排除标准
- •Any chronic major medical comorbid condition deemed by the Investigator as presenting added risk to the subject, including but not limited to, refractory hypertension, kidney disease, or liver disease
- •Diagnosed with diabetes (Type 1 or II) or receiving any anti-diabetic medication
- •Unstable seizure disorder, defined by any seizure within 6 months prior to baseline visit and/or a change in any anti-convulsant drug dosing in the 60 days prior to study consent
- •Changes in psychotropic or anti-convulsant (where taken for reasons other than seizure control) drug treatment within 30 days prior to Screening
- •Significant changes in any educational, behavioral, and/or dietary interventions the month prior to Screening
- •Planned initiation of new, or modification of ongoing, interventions during the study
- •Unable or unwilling to take oral medication (whole capsule, despite assistance with a spoonful of applesauce, yoghurt, or equivalent liquid food)
- •Consumption of liver enzyme inducers or inhibitors including and not limited to foods, medicines, herbal remedies and supplements three days prior to any Visit. Foods or beverages containing CYP3A4/5 inhibitors (e.g., grapefruit, pomegranate, pomelo, and star fruit) should be avoided before taking study medication and for up to 1 hour post dose throughout the study
- •Has abnormal baseline laboratory assessments including, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin >1.5 × the upper limit of normal (ULN), serum creatinine >1.5 x ULN or other clinically relevant laboratory abnormality
- •Has a clinically significant heart rate or blood pressure (BP) at Screening as judged by the Investigator
- •Has received an investigational drug in any prior clinical study within 30 days or 5 half-lives (whichever is longer) prior to Screening
研究组 & 干预措施
All Study Participants
Participants received, in random order, a single dose of placebo or Gaboxadol with a two-week washout period between doses. The gaboxadol dosage selected for this study is 10 mg or Placebo as a single dose on each study visit (two at home and two in clinic).
干预措施: Gaboxadol (Drug)
All Study Participants
Participants received, in random order, a single dose of placebo or Gaboxadol with a two-week washout period between doses. The gaboxadol dosage selected for this study is 10 mg or Placebo as a single dose on each study visit (two at home and two in clinic).
干预措施: Placebo (Drug)
结局指标
主要结局
To evaluate target engagement of gaboxadol treatment on high density EEG recordings
时间窗: Pre-dose, 60 minutes post-dose
Changes in EEG recordings with gaboxadol treatment (60-90 minutes post-dose compared with pre-dose on resting theta, alpha and gamma band relative and absolute power; brain response to auditory chirp stimuli in the gamma band range).
次要结局
- To investigate the feasibility of high density EEG recording at home in adult males with FXS(Pre-dose, 60 minutes post-dose)
- To investigate the effect of gaboxadol treatment on eye tracking assessments(Pre-dose, 60 minutes post-dose)
- To determine whether FMRP levels predict treatment response(Pre-dose and post-dose)
- To investigate the effect of gaboxadol treatment on clinician-rated measures(Pre-dose and post-dose)
- To potentially explore the pharmacokinetics of gaboxadol treatment in single-dose trial design(Pre-dose, 60 minutes post-dose)
- To investigate the feasibility of home research visits and procedures in adult males with FXS(Pre-dose, 60 minutes post-dose)
- To investigate the effect of gaboxadol treatment on neuropsychological assessments(Pre-dose, 60 minutes post-dose)
研究者
Craig Erickson
Research Director and Research Endowed Professor
Children's Hospital Medical Center, Cincinnati